Agios Pharmaceuticals, Inc.

NasdaqGS AGIO

Agios Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -402.63 M

Agios Pharmaceuticals, Inc. EBITDA is USD -402.63 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -6.70% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Agios Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -377.35 M, a 2.18% change year over year.
Agios Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -385.75 M, a -9.21% change year over year.
Agios Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -353.23 M, a 2.24% change year over year.
Agios Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -361.33 M, a 9.12% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: AGIO

Agios Pharmaceuticals, Inc.

CEO	Mr. Brian M. Goff M.B.A.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street
Employees	383
Sector	Health Care
Industries Pharmaceuticals Biotechnology Petrochemicals

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years